An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials
Colin J. Henderson, Yury Kapelyukh, Nico Scheer et al. · Drug Metabolism and Disposition · 2019
Species differences in drug metabolism and disposition can confound the extrapolation of in vivo PK data to man and also profoundly compromise drug efficacy studies owing to differences in pharmacokinetics, in metabolites produced (which are often pharmacologically active), and in differential activation of the transcription factors constitutive androstane receptor (CAR) and pregnane X receptor (PXR), which regulate the expression of such enzymes as P450s and drug transporters. These differences have gained additional importance as a consequence of the use of genetically modified mouse models for drug-efficacy testing and also patient-derived xenografts to predict individual patient responses to anticancer drugs. A number of humanized mouse models for cytochrome P450s, CAR, and PXR have been reported. However, the utility of these models has been compromised by the redundancy in P450 reactions across gene families, whereby the remaining murine P450s can metabolize the compounds being tested. To remove this confounding factor and create a mouse model that more closely reflects human pathways of drug disposition, we substituted 33 murine P450s from the major gene families involved in drug disposition, together with Car and Pxr, for human CAR, PXR, CYP1A1, CYP1A2, CYP2C9, CYP2D6, CYP3A4, and CYP3A7. We also created a mouse line in which 34 P450s were deleted from the mouse genome. Using model compounds and anticancer drugs, we demonstrated how these mouse lines can be applied to predict drug-drug interactions in patients and discuss here their potential application in the more informed design of clinical trials and the personalized treatment of cancer.
Cited by 44 works. doi:10.1124/dmd.119.086397 Open-access PDF
Authors
- Colin J. Henderson
- Yury Kapelyukh
- Nico Scheer
- Anja Rode
- Aileen W. McLaren
- A. Kenneth MacLeod
- De‐Chen Lin
- Lesley A. Stanley
- C. Roland Wolf
References
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
- The Carbon Monoxide-binding Pigment of Liver Microsomes
- Can the pharmaceutical industry reduce attrition rates?
- Dose translation from animal to human studies revisited
- The extinction coefficient of cytochrome c
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010
- Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib